RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.

Inclusion Criteria:

1. Suitable candidate for intra-cardiac mapping and ablation of atrial arrhythmiasincluding atrial fibrillation, atrial flutter and/or atrial tachycardia

2. Above eighteen (18) years of age or of legal age to give informed consent specificto state and national law

3. Left atrial (LA) diameter ≤ 5.5 cm or LA volume index ≤ 50 mL/m2 (use whichevermeasure is available or if both available, use the lesser of the two to qualify)

Exclusion Criteria:

1. De Novo paroxysmal AF

2. AF from a reversible cause (e.g., surgery, hyperthyroidism, sarcoidosis, orpericarditis, etc.)

3. Cardiac surgery or intervention within the past 90 days (e.g. percutaneous coronaryintervention, ablation for ventricular arrhythmias, left atrial appendage occlusiondevices, atrial septal defect closure devices, transcatheter aortic valvereplacement)

4. Presence of transvenous pacing or defibrillator leads or an atrial leadlesspacemaker

5. Myocardial infarction within the past 90 days

6. Severe valvular disease or prosthetic valve(s)

7. Contraindication to therapeutic anticoagulation

8. Decompensated heart failure or New York Heart Association (NYHA) Functional Class IV

9. Positive pregnancy test

10. Any other contraindication to an intracardiac mapping and ablation of atrialarrhythmias

11. Enrollment in another investigational study evaluating another device, biologic ordrug